Stryker director sells beaucoup shares; Crowdfunding blunts device app regulatory demands;

@FierceMedDev: Enzymatics jumps into next-gen Dx space with $50M startup buy. More | Follow @FierceMedDev

@MarkHFierce: Better sanitation is linked to more Alzheimer's cases. Article | Follow @MarkHFierce

@MichaelGFierce: Myriad rolls out next-gen Dx for 8 major cancers. Story | Follow @MichaelGFierce

> A Stryker ($SYK) director has sold more than $1.4 million in shares of common stock. Story

> Makers of medical device apps are turning to crowdfunding to help support new demands created by FDA regulatory oversight. Story

> A new coating helped reduce the blood clot risk inside stents in an animal study. Item

> VirtualScopics ($VSCP) says it has regained compliance with the minimum $1 share bid price requirement for the Nasdaq stock market. The Rochester, NY, company makes imaging technology used for medical device and drug development. Item

> StelKast in Pennsylvania won the FDA's 510(k) clearance to market EXp, which is intended to boost the durability of its Proven Gen-Flex total knee system. Item

Biotech News

@FierceBiotech: In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Article from FierceBiotech IT | Follow @FierceBiotech

@JohnCFierce: Crowdfunding cash for biotech startup Perle (diabetes). Press release | Follow @JohnCFierce

@Ry_McBride: UPDATED: No end of biotech IPO frenzy in sight. Special report | Follow @Ry_McBride

@EmilyMFierce: Making iPS cells safer for use in humans through the study of a cellular odd fellow. More from Stanford | Follow @EmilyMFierce

> Novartis strikes stem cell deal to aid transplant patients. Story

NYT: Blech says he could have been a biotech billionaire. Article

> Under FDA priority review, Mallinckrodt's pain med succeeds in PhIII. More

Pharma News

@FiercePharma: Glaxo said to be near $1.6B Lucozade-Ribena sale to Japan's Suntory. Latest in series of brand sales. ICYMI yesterday | Follow @FiercePharma

@EricPFierce: Bristol-Myers Squibb flees high cost of East Coast with new center in Tampa, FL. Moving some jobs from NJ. Report | Follow @EricPFierce

@CarlyHFierce: Departure of new Vivus CEO Zook tops the list of this week's hirings, firings & other movements in pharma/biotech. Chutes & Ladders | Follow @CarlyHFierce

> Would GSK pull out of China altogether? More

> 'Doctor-2' in Elan, Wyeth insider trading case said to be well connected Alzheimer's doc. Article

> Another compounder recalls drugs because of lapse in outside testing. Story

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.